The results show that the combined administration of an antibody against TCR/CD3 and an antibody against TNF-α is the minimum requirement for achieving a long-term therapy success, as documented by a sustained suppression of autoimmunity in connection with the abolishment of the beta cell toxic effect of the proinflammatory cytokine TNF-α. Here, TNF is linked to Autoimmunity.